October 13, 2017
Kemin launches anticoccidial COZANTE in APAC poultry markets
Kemin Industries has launched its latest anticoccidial innovation, COZANTE™, in Asia Pacific poultry feed markets.
"In an era of responsible antibiotic use in livestock, anticoccidials can help improve the availability of high quality and affordable protein," said Dr. Alfred Chua, marketing director for animal nutrition and health, Asia Pacific. "Kemin is leading the way with anticoccidial innovation to meet the growing consumer demand for safe, wholesome protein."
COZANTE requires no withdrawal period and has been shown to control Eimeria spp. either in synergistic association with ionophores or as a standalone in coccidiostat-free farming. It has a unique mode of action compared to chemicals and ionophores to ensure no cross-resistance in poultry.
To significantly enhance the bioavailability of the new anticoccidial molecule at the target site of Eimeria infection, COZANTE is encapsulated using Kemin MicroPEARL™ technology.
"COZANTE is a natural molecule derived from a medicinal plant widely recognised for centuries in the eastern Mediterranean countries," said Chua. "Kemin is committed to providing the feed industry with safe, well-studied ingredients that are in line with consumer advocacy groups and regulatory guidelines."
In September, Kemin hosted the "International COZANTE Event & IHSIG 2017" in Kaohsiung, Taiwan. The event was attended by more than 80 livestock integrators and top feed mills guests to celebrate the launch of COZANTE for poultry feeds.
Event highlights included: professor Tsai Hsiang Jung at the National Taiwan University School of Veterinary Medicine in Taiwan, shared his in-depth research on coccidiosis; Nikolai Ongena, poultry veterinarian and consultant for Vetworks in Belgium, shared insights for managing gut health using antibiotic alternatives and demonstrated how to perform lesion scoring in broilers; Koh Thong Jin, product manager for animal nutrition and health, Asia Pacific, shared the results of animal trials using COZANTE.